Objective: In this study, we aimed to present the treatments administered to patients with primary gastric lymphoma who were treated in the hematology and oncology clinics of our center, as well as the survival rates and the differences between the subgroups.

Materials and Methods: The data of patients diagnosed with primary gastric lymphoma and those treated between January 2000 and January 2022 were retrospectively reviewed. Certain biochemical parameters of the patients, the chemotherapy regimens they received, whether they received surgical treatment, radiotherapy or both, their overall survival (OS) and progression-free survival (PFS) rates, and intergroup differences were investigated.

Results: The study included 27 patients. Of these, 10 (41.2%) were diagnosed with mucosa-associated lymphoid tissue (MALT) lymphoma and 17 (58.8%) were diagnosed with diffuse large B-cell lymphoma (DLBCL). At the time of diagnosis, 10, 3, 2, and 12 patients were in stages I, II, IIE, and IV, respectively, according to the Lugano staging. According to the Ann–Arbor staging, 9, 5, 1, and 12 patients were in stages I, II, III, and IV, respectively. Of the 21 patients receiving systemic chemotherapy, 19 received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), 1 received CHOP, and 1 received rituximab, cyclophosphamide, vincristine, and prednisone treatments. There was a significant difference between the two groups in terms of neutrophil levels and Ki-67 percentages (p=0.027, p=0.0144, respectively). The median OS was 162.3 (1–233) months in patients diagnosed with MALT lymphoma, whereas the median OS for patients diagnosed with DLBCL could not be reached (2–80 months; p=0.57).

Conclusion: The present study showed that patients with primary gastric non-hodgkin lymphoma (NHL), regardless of the subtype being MALT or DLBCL, may have longer OS and PFS. At the time of diagnosis, Helicobacter pylori positivity and eradication should not be overlooked, especially in MALT lymphomas, keeping in mind that the neutrophil count may be associated with OS in the DLBCL type.